Policy changes could make esketamine more affordable for treatment-resistant depression

A joint research team led by the LKS Faculty of Medicine of the University of Hong Kong (HKUMed), in collaboration with The Chinese University of Hong Kong, New York University and Newcastle University, has found that a combination of policies and service measures could enhance the value and affordability of esketamine nasal spray, a novel rapid-acting treatment for adults with treatment-resistant depression (TRD) in Hong Kong.

Read it at Medical Xpress ↗

← Front page